Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vermillion Takes Control: Dx Firm Launches Its Own Lab To Market Ovarian Cancer Test

This article was originally published in The Gray Sheet

Executive Summary

Not happy with market penetration since its FDA-cleared OVA1 ovarian cancer molecular assay launched exclusively via Quest Diagnostics in 2009, Vermillion has launched ASPiRA Labs to more directly connect with OB-GYN customers.

You may also be interested in...



Quest, Vermillion Begin U.S. Marketing Push For Ovarian Cancer Test

Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

'Hunker Down, Expect The Worst And Hope For The Best:' Investment Analyst Advises Medtech Businesses To Cut Costs

Maxim Jacobs, managing partner at Edison Investment Research urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.

Topics

Related Companies

UsernamePublicRestriction

Register

MT033013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel